SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.

Wednesday, October 28, 2020

SFJ Pharmaceuticals® ("SFJ") is pleased to note that its partner Apellis Pharmaceuticals Inc. ("Apellis") (Waltham, MA) and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases including paroxysmal nocturnal hemoglobinuria (PNH). 

Under the terms of the agreement, Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for pegcetacoplan, including for hematologic indications. The strategic partnership allows Apellis to leverage Sobi's commercial capabilities and leadership in hematology and rare diseases to drive potential first regulatory approval in PNH and accelerate its internationalization.

A link to the announcement by Apellis can be found at https://investors.apellis.com/news-releases.

SFJ entered a novel risk-sharing collaboration with Apellis to develop pegcetacoplan in hematologic indications in February 2019.

Latest Issue
Get instant
access to our latest e-book
Thermo Fisher Scientific - Chromatography Solutions Eppendorf - Discover the Flow Meco - 90 years